Placebo News and Research

RSS

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Exploring the role of suvorexant in reducing delirium among older adults

Delirium is a sudden onset and temporary state of disturbed consciousness or cognition, occurring due to underlying medical issues like fever or alcohol withdrawal.

29 Aug 2024

TCT 2024 to feature latest advances in interventional cardiovascular medicine

The Cardiovascular Research Foundation is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

28 Aug 2024

High-dose psilocybin shows promise for depression treatment

Researchers compare the effectiveness and acceptability of oral monotherapy with psychedelics for the treatment of depressive symptoms.

27 Aug 2024

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Anti-obesity medication may help to prevent heart attacks and other major cardiac events

The anti-obesity medication semaglutide may help to prevent heart attacks and other major adverse cardiac events among overweight people who have cardiovascular disease, whether or not they also have heart failure, according to a new study led by UCL's Professor John Deanfield.

22 Aug 2024

Investigational drug reduces hot flashes associated with menopause

The investigational drug elinzanetant significantly reduces the frequency and severity of hot flashes associated with menopause while improving women's quality of life, new UVA Health research published in the prestigious Journal of the American Medical Association shows.

22 Aug 2024

Expanded use of common antibiotic cuts child mortality by 14% in Sub-Saharan Africa

When UC San Francisco research showed that routinely treating children in Sub-Saharan Africa with a common antibiotic could reduce deaths in children under five, the World Health Organization (WHO) moved quickly to recommend the treatment – but only for infants between 1 and 11 months old.

22 Aug 2024

High dose psilocybin shows similar antidepressant effects to escitalopram

High doses of psilocybin - the active ingredient in magic mushrooms - appears to have a similar effect on depressive symptoms as the selective serotonin reuptake inhibitor (SSRI) drug escitalopram, suggests a systematic review and meta-analysis published in The BMJ today.

21 Aug 2024

Camu-camu extract reduces liver fat in non-alcoholic fatty liver disease

A research team from Université Laval has shown the benefits of camu-camu on non-alcoholic fatty liver disease, which affects over seven million people in Canada.

21 Aug 2024

Aceneuramic acid drug receives approval for treatment of patients with GNE myopathy

In order to treat an underserved population of patients with a rare condition whose muscles gradually become weaker until they can no longer walk, a team of researchers across Japan have completed a clinical study to confirm the safety of long-term administration of a therapeutic drug.

20 Aug 2024

Tecovirimat shows no significant impact on mpox lesion duration in DRC study

The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an initial analysis of data from a randomized, placebo-controlled trial.

16 Aug 2024

Breakthrough malaria vaccine offers long-term protection for pregnant women

In a report published in The Lancet Infectious Diseases (Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials) a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable protective efficacy against malaria shown by Sanaria® PfSPZ Vaccine when administered to women prior to pregnancy.

14 Aug 2024

Experimental malaria vaccine shows promise in protecting pregnant women

Two National Institutes of Health (NIH)-supported trials of an experimental malaria vaccine in healthy Malian adults found that all three tested regimens were safe.

14 Aug 2024

KERI advances neuromodulation technology for appetite suppression in obesity treatment

The R&D on neuromodulation technology for the treatment and management of metabolic syndrome conducted by a team led by Dr. Ki-young Shin of Human Care Electro-Medical Device Research Center, Electro-Medical Equipment Research Division of KERI is underway smoothly.

14 Aug 2024

Placebo News and Research

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Vutrisiran shows potential to become the new standard of care for rare heart disease

Exploring the role of suvorexant in reducing delirium among older adults

TCT 2024 to feature latest advances in interventional cardiovascular medicine

High-dose psilocybin shows promise for depression treatment

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Anti-obesity medication may help to prevent heart attacks and other major cardiac events

Investigational drug reduces hot flashes associated with menopause

Expanded use of common antibiotic cuts child mortality by 14% in Sub-Saharan Africa

High dose psilocybin shows similar antidepressant effects to escitalopram

Camu-camu extract reduces liver fat in non-alcoholic fatty liver disease

Aceneuramic acid drug receives approval for treatment of patients with GNE myopathy

Tecovirimat shows no significant impact on mpox lesion duration in DRC study

Breakthrough malaria vaccine offers long-term protection for pregnant women

Experimental malaria vaccine shows promise in protecting pregnant women

KERI advances neuromodulation technology for appetite suppression in obesity treatment

New findings reveal how serotonin shapes behavior in negative situations

Stretching and meditation ease nocturnal muscle cramps in cirrhosis patients

KERI's transcranial random noise stimulation shows promise for metabolic syndrome treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News